Skip to main content
. 2019 Jul 22;7(3):221–225. doi: 10.14218/JCTH.2019.00018

Fig. 1. Mean plasma HCV RNA change during the treatment of all the patients who completed the treatment.

Fig. 1.

The HCV RNA levels of all individual patients declined rapidly after initiation of treatment with DNVr plus pegylated-interferon α-2a and ribavirin on week 1. Plasma HCV RNA was quantified at screening and at each visit thereafter to assess the virologic response to treatment. Plasma HCV RNA was recorded as 1 IU/mL (equal to 1 log10 IU/mL) if HCV RNA <15 IU/mL (lower limit of quantitation) or target not detected.

Abbreviations: HCV, hepatitis C virus; DNVr, ritonavir-boosted danoprevir; EOT, end of treatment; SVR12, sustained virologic response at 12 weeks after treatment; SVR24, sustained virologic response at 24 weeks after treatment.